Showing results (521-530 of 782) with videos related to

Sort By:
Pageof 79
Blood|March 16, 2025
Loss of BCL7A Permits IRF4 Transcriptional Activity and Cellular Growth in Multiple MyelomaChandraditya Chakraborty, Srikanth Talluri, Moritz Binder, et al.
British Journal of Haematology|January 21, 2016
Clinical utility of C-terminal telopeptide of type 1 collagen in multiple myelomaKay R Ting, Jennifer J Brady, Abdul Hameed, et al.
Cancer Research Communications|September 8, 2023
Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction TreatmentJiahui Liu, Wenqiang Yan, Huishou Fan, et al.
Blood|October 27, 2023
Differentiation of BCMA-specific induced pluripotent stem cells into rejuvenated CD8αβ+ T cells targeting multiple myelomaJooeun Bae, Shuichi Kitayama, Zach Herbert, et al.
Blood|February 12, 2005
Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivoMakoto Hamasaki, Teru Hideshima, Pierfrancesco Tassone, et al.
British Journal of Haematology|April 25, 2007
Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myelomaPaul G Richardson, Pieter Sonneveld, Michael W Schuster, et al.
British Journal of Haematology|December 19, 2006
BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growthHiroshi Yasui, Teru Hideshima, Hiroshi Ikeda, et al.
Therapeutic Advances in Medical Oncology|January 22, 2024
Longitudinal genetically detectable minimal residual disease by fluorescence in situ hybridization confers a poor prognosis in myelomaJian Cui, Tengteng Yu, Rui Lv, et al.
International Journal of Cancer|December 19, 2022
Dysfunctions of innate and adaptive immune tumor microenvironment in Waldenström macroglobulinemiaDanka Cholujova, Gabor Beke, Zachary R Hunter, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 31, 2016
VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple MyelomaDavid S Siegel, Meletios Dimopoulos, Sundar Jagannath, et al.
Pageof 79